NCT06227156 2024-05-23Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate CancerRemeGen Co., Ltd.Phase 2 Recruiting40 enrolled